Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,649
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
stocks
ASX energy giant undervalued despite commissioning challenges
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.80 | 29.80 | 0.33% |
| CAC 40 | 8,458.78 | 52.72 | 0.63% |
| DAX 40 | 25,464.01 | 102.98 | 0.41% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,871.02 | 89.27 | 0.83% |
| HKSE | 25,657.66 | 346.81 | 1.37% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 60,741.93 | 1,622.99 | -2.60% |
| NZX 50 Index | 13,965.75 | 103.82 | 0.75% |
| S&P 500 | 7,428.78 | 15.60 | 0.21% |
| S&P/ASX 200 | 9,037.10 | 33.60 | 0.37% |
| SSE Composite Index | 3,793.18 | 20.13 | -0.53% |